Tatiana A. Voronina
Research Subjects
Research Interests
Tatiana A. Voronina has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- L. N. Nerobkova
Zakusov Institute of Pharmacology
26 shared publications - Svetlana A. Litvinova
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
23 shared publications - Elena A. Ivanova
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
13 shared publications - Инга Геннадиевна Капица
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
12 shared publications - Anastasia G. Vasilchuk
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
10 shared publications - A. I. Matyushkin
НИИ фармакологии имени В. В. Закусова
9 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 5-21
Cardioneurology and neurocardiology are two sides of the same problem
Relevance. Cardiovascular and cerebrovascular diseases remain leading causes of disability and mortality. Recent evidence indicates a close bidirectional relationship between the heart and the brain, mediated by autonomic, neurohumoral, and inflammatory mechanisms. This interplay is conceptualized within cardioneurology and neurocardiology. Objective. Drawing on current scientific understanding of the new, interdisciplinary, and mutually complementary field of medical science known as cardioneurology/neurocardiology, this text aims to introduce the reader to the key disease entities responsible for the development of the pathological bidirectional brain–heart axis and to demonstrate the importance of an interdisciplinary approach to studying this combined pathology. Methods. A narrative review of publications from PubMed, Scopus, and eLIBRARY predominantly over the last 20 years addressing pathophysiological and clinical aspects of cardioneurological and neurocardiological interactions was performed. Results. The first part of the review examines stroke-mediated pathological alterations in cardiac functional activity (ECG changes, arrhythmias, myocardial infarction, heart failure, sudden cardiac death of neurological origin, and Takotsubo syndrome), while the second part addresses cardiac risk factors that precipitate cerebrovascular disorders (atrial fibrillation, arterial hypertension, chronic heart failure, ischemic heart disease, and cardiomyopathies, including alcoholic cardiomyopathy). Conclusion. Integrating knowledge on the ‘brain–heart’ axis creates new opportunities for developing comprehensive therapeutic approaches aimed at dual protection of both organs. Further research should focus on identifying specific biomarkers and targets for personalized therapy.
- 16 October 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 5-21
Open AccessCardioneurology and neurocardiology are two sides of the same problem
Relevance. Cardiovascular and cerebrovascular diseases remain leading causes of disability and mortality. Recent evidence indicates a close bidirectional relationship between the heart and the brain, mediated by autonomic, neurohumoral, and inflammatory mechanisms. This interplay is conceptualized within cardioneurology and neurocardiology. Objective. Drawing on current scientific understanding of the new, interdisciplinary, and mutually complementary field of medical science known as cardioneurology/neurocardiology, this text aims to introduce the reader to the key disease entities responsible for the development of the pathological bidirectional brain–heart axis and to demonstrate the importance of an interdisciplinary approach to studying this combined pathology. Methods. A narrative review of publications from PubMed, Scopus, and eLIBRARY predominantly over the last 20 years addressing pathophysiological and clinical aspects of cardioneurological and neurocardiological interactions was performed. Results. The first part of the review examines stroke-mediated pathological alterations in cardiac functional activity (ECG changes, arrhythmias, myocardial infarction, heart failure, sudden cardiac death of neurological origin, and Takotsubo syndrome), while the second part addresses cardiac risk factors that precipitate cerebrovascular disorders (atrial fibrillation, arterial hypertension, chronic heart failure, ischemic heart disease, and cardiomyopathies, including alcoholic cardiomyopathy). Conclusion. Integrating knowledge on the ‘brain–heart’ axis creates new opportunities for developing comprehensive therapeutic approaches aimed at dual protection of both organs. Further research should focus on identifying specific biomarkers and targets for personalized therapy.
- Open Access
- 16 October 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 125-134
Effect of melatonin on behavioral features of Wistar rats with an autism spectrum disorder model induced by prenatal propionic acid administration
Background. Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders characterized by deficits in social interaction, stereotyped behavior, and comorbid conditions (anxiety, cognitive impairments, and others). Prenatal administration of propionic acid (PPA) reproduces a complex of ASD like behavioral changes in rats. Melatonin has antioxidant, anti inflammatory and mitochondria protective effects, making it a promising candidate for the correction of these disorders. Objective. To study the effect of melatonin on behavioral impairments in male Wistar rats in a model of ASD induced by prenatal PPA administration. Methods . PPA was administered subcutaneously at a dose of 500 mg/kg to female rats on gestation days 12–16. The offspring were divided into the following groups: control, PPA, and PPA + melatonin. Melatonin (3 mg/kg) or distilled water was administered orally from postnatal day 6 to 70. Rat behavior was assessed in tests: Open Field, Elevated Plus Maze, Y maze, Paired test, Hole board test, Autogrooming, Three chamber social test, and Novel Object Recognition. Results. PPA exposed rats showed reduced sociability and exploratory activity, increased anxiety, stereotypy and aggression, and cognitive impairment. Melatonin significantly corrected these impairments: it increased communicative behavior by 3.1 times and decreased aggressive manifestations by 3.7 times in the Paired test; increased the duration of contact with a social object by 4.8 times and the social preference coefficient by 2.1 times; decreased grooming duration by 2.1–3.2 times; reduced anxiety (a 13 fold increase in the number of entries into the center of the open field); improved cognitive performance in the Y maze (a 2.6 fold increase in patrolling efficiency) and in the Novel Object Recognition (an increase in preference for the novel object by 2.1 times in the number of approaches and by 5.2 times in the time spent in the arm containing it). Conclusion. Melatonin at a dose of 3 mg/kg with long term oral administration attenuates the main and comorbid behavioral impairments in male rats with the prenatal PPA induced ASD model, substantiating its further study as a pharmacological correction agent.
- 16 October 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 125-134
Open AccessEffect of melatonin on behavioral features of Wistar rats with an autism spectrum disorder model induced by prenatal propionic acid administration
Background. Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders characterized by deficits in social interaction, stereotyped behavior, and comorbid conditions (anxiety, cognitive impairments, and others). Prenatal administration of propionic acid (PPA) reproduces a complex of ASD like behavioral changes in rats. Melatonin has antioxidant, anti inflammatory and mitochondria protective effects, making it a promising candidate for the correction of these disorders. Objective. To study the effect of melatonin on behavioral impairments in male Wistar rats in a model of ASD induced by prenatal PPA administration. Methods . PPA was administered subcutaneously at a dose of 500 mg/kg to female rats on gestation days 12–16. The offspring were divided into the following groups: control, PPA, and PPA + melatonin. Melatonin (3 mg/kg) or distilled water was administered orally from postnatal day 6 to 70. Rat behavior was assessed in tests: Open Field, Elevated Plus Maze, Y maze, Paired test, Hole board test, Autogrooming, Three chamber social test, and Novel Object Recognition. Results. PPA exposed rats showed reduced sociability and exploratory activity, increased anxiety, stereotypy and aggression, and cognitive impairment. Melatonin significantly corrected these impairments: it increased communicative behavior by 3.1 times and decreased aggressive manifestations by 3.7 times in the Paired test; increased the duration of contact with a social object by 4.8 times and the social preference coefficient by 2.1 times; decreased grooming duration by 2.1–3.2 times; reduced anxiety (a 13 fold increase in the number of entries into the center of the open field); improved cognitive performance in the Y maze (a 2.6 fold increase in patrolling efficiency) and in the Novel Object Recognition (an increase in preference for the novel object by 2.1 times in the number of approaches and by 5.2 times in the time spent in the arm containing it). Conclusion. Melatonin at a dose of 3 mg/kg with long term oral administration attenuates the main and comorbid behavioral impairments in male rats with the prenatal PPA induced ASD model, substantiating its further study as a pharmacological correction agent.
- Open Access
- 22 July 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 59-66
Fabomotizole corrects behavioral impairments in a postnatal propionic acid model of autism spectrum disorders in rats
Background. Postnatal administration of propionic acid (PPA) to rats during the period of active neural network maturation models persistent behavioral disorders characteristic of autism spectrum disorders (ASD). Fabomotizole, which has a multifactorial mechanism of action (sigma-1 receptor activation, modulation of GABAergic and glutamatergic transmission), may have a corrective effect on these disorders. Objective. To study the effect of fabomotizole on behavioral disorders in Wistar rats with an ASD model induced by postnatal PPA administration. Methods. ASD was modeled in male Wistar rats by subcutaneous injections of PPA at a dose of 500 mg/kg on postnatal days 21–25 (P21–P25). Fabomotizole (10 mg/kg) was administered orally daily from P26 until the end of the experiment. Between P52 and P85, social behavior (Pair Test), stereotypy (Autogrooming), anxiety (Open Field Test, Elevated Plus Maze), exploratory activity (Hole Board Test), cognitive functions (Y-maze), and response to aversive odor were assessed. Results. Postnatal PPA administration caused persistent impairments: social deficit (4.3-fold decrease in communicative acts, 26-fold increase in aggression), stereotypy (6.4-fold increase in grooming duration), anxiety (4.4-fold decrease in time spent in open arms), cognitive deficit (2.2-fold decrease in Y-maze patrolling efficiency), and disrupted species-specific behavior. Fabomotizole corrected the PPA-induced impairments: normalized social behavior (4.6-fold increase in communicative acts, 10.5-fold decrease in aggression), reduced stereotypy (5.5-fold decrease in grooming duration), exerted an anxiolytic effect (8.5-fold increase in time spent in open arms), and improved cognitive functions (2.7-fold increase in patrolling efficiency). Conclusion. Fabomotizole at a dose of 10 mg/kg with long-term oral administration attenuates the main behavioral disorders in rats with the postnatal PPAinduced ASD model, confirming its therapeutic potential against persistent symptoms of autism spectrum disorder.
- 22 July 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 59-66
Open AccessFabomotizole corrects behavioral impairments in a postnatal propionic acid model of autism spectrum disorders in rats
Background. Postnatal administration of propionic acid (PPA) to rats during the period of active neural network maturation models persistent behavioral disorders characteristic of autism spectrum disorders (ASD). Fabomotizole, which has a multifactorial mechanism of action (sigma-1 receptor activation, modulation of GABAergic and glutamatergic transmission), may have a corrective effect on these disorders. Objective. To study the effect of fabomotizole on behavioral disorders in Wistar rats with an ASD model induced by postnatal PPA administration. Methods. ASD was modeled in male Wistar rats by subcutaneous injections of PPA at a dose of 500 mg/kg on postnatal days 21–25 (P21–P25). Fabomotizole (10 mg/kg) was administered orally daily from P26 until the end of the experiment. Between P52 and P85, social behavior (Pair Test), stereotypy (Autogrooming), anxiety (Open Field Test, Elevated Plus Maze), exploratory activity (Hole Board Test), cognitive functions (Y-maze), and response to aversive odor were assessed. Results. Postnatal PPA administration caused persistent impairments: social deficit (4.3-fold decrease in communicative acts, 26-fold increase in aggression), stereotypy (6.4-fold increase in grooming duration), anxiety (4.4-fold decrease in time spent in open arms), cognitive deficit (2.2-fold decrease in Y-maze patrolling efficiency), and disrupted species-specific behavior. Fabomotizole corrected the PPA-induced impairments: normalized social behavior (4.6-fold increase in communicative acts, 10.5-fold decrease in aggression), reduced stereotypy (5.5-fold decrease in grooming duration), exerted an anxiolytic effect (8.5-fold increase in time spent in open arms), and improved cognitive functions (2.7-fold increase in patrolling efficiency). Conclusion. Fabomotizole at a dose of 10 mg/kg with long-term oral administration attenuates the main behavioral disorders in rats with the postnatal PPAinduced ASD model, confirming its therapeutic potential against persistent symptoms of autism spectrum disorder.
- Open Access
- 13 April 2026
- Published by Moscow University Press in Vestnik Moskovskogo universiteta. Seria 16. Biologia
- Vol. 81 (2026-1) , 24
The effect of the BDNF mimetic GSB-106 on behavior and inflammation levels in Wistar rats with experimental autism spectrum disorder
Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders characterized by defi cits in social interaction, stereotypic behavior, and restricted interests. In ASD, dysregulation of proteins associated with synaptic plasticity, particularly brain-derived neurotrophic factor (BDNF), as well as elevated levels of infl ammation, are observed. Investigating the involvement of BDNF in the pathogenesis of ASD and the search for new therapeutic agents represent an important task in psychopharmacology. The aim of this study was to investigate the eff ects of the low-molecular-weight dipeptide BDNF mimetic hexamethylenediamide bis(N-monosuccinyl-L-seryl-L-lysine) (GSB-106) on behavioral features and infl ammation in rats with experimental ASD. ASD was modeled by administering sodium valproate at a dose of 600 mg/kg to female Wistar rats on gestational day 12.5. The off spring (both males and females) received GSB-106 orally at a dose of 0.1 mg/kg daily from postnatal day 7 (P7) to P81. From P39 to P81, stereotypic behavior, exploratory and locomotor activity, and pain sensitivity were assessed, followed by evaluation of infl ammation by measuring complement system activity and the content of multiple-modifi ed low-density lipoproteins (mmLDL). GSB-106 at a dose of 0.1 mg/kg reduced stereotypy 2.0-fold (p < 0.05), increased exploratory activity 1.3-fold (p < 0.05), and improved locomotor coordination 1.5-fold (p < 0.05) in male rats with ASD compared to the VPA group. In female rats with ASD, GSB-106 increased the pain threshold 1.2-fold (p < 0.05) and improved locomotor coordination 1.9-fold (p < 0.001). The eff ect of GSB-106 on metabolic and oxidative processes associated with infl ammation was observed only in male rats with experimental ASD, as evidenced by a 39.9% reduction (p < 0.01) in serum mmLDL levels compared with the VPA group. The obtained results indicate the involvement of BDNF in the pathogenesis of ASD and suggest that GSB-106 may be considered a promising compound for further development as a therapeutic agent for correcting behavioral disturbances characteristic of ASD.
- 13 April 2026
- Published by Moscow University Press in Vestnik Moskovskogo universiteta. Seria 16. Biologia
- Vol. 81 (2026-1) , 24
Open AccessThe effect of the BDNF mimetic GSB-106 on behavior and inflammation levels in Wistar rats with experimental autism spectrum disorder
Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders characterized by defi cits in social interaction, stereotypic behavior, and restricted interests. In ASD, dysregulation of proteins associated with synaptic plasticity, particularly brain-derived neurotrophic factor (BDNF), as well as elevated levels of infl ammation, are observed. Investigating the involvement of BDNF in the pathogenesis of ASD and the search for new therapeutic agents represent an important task in psychopharmacology. The aim of this study was to investigate the eff ects of the low-molecular-weight dipeptide BDNF mimetic hexamethylenediamide bis(N-monosuccinyl-L-seryl-L-lysine) (GSB-106) on behavioral features and infl ammation in rats with experimental ASD. ASD was modeled by administering sodium valproate at a dose of 600 mg/kg to female Wistar rats on gestational day 12.5. The off spring (both males and females) received GSB-106 orally at a dose of 0.1 mg/kg daily from postnatal day 7 (P7) to P81. From P39 to P81, stereotypic behavior, exploratory and locomotor activity, and pain sensitivity were assessed, followed by evaluation of infl ammation by measuring complement system activity and the content of multiple-modifi ed low-density lipoproteins (mmLDL). GSB-106 at a dose of 0.1 mg/kg reduced stereotypy 2.0-fold (p < 0.05), increased exploratory activity 1.3-fold (p < 0.05), and improved locomotor coordination 1.5-fold (p < 0.05) in male rats with ASD compared to the VPA group. In female rats with ASD, GSB-106 increased the pain threshold 1.2-fold (p < 0.05) and improved locomotor coordination 1.9-fold (p < 0.001). The eff ect of GSB-106 on metabolic and oxidative processes associated with infl ammation was observed only in male rats with experimental ASD, as evidenced by a 39.9% reduction (p < 0.01) in serum mmLDL levels compared with the VPA group. The obtained results indicate the involvement of BDNF in the pathogenesis of ASD and suggest that GSB-106 may be considered a promising compound for further development as a therapeutic agent for correcting behavioral disturbances characteristic of ASD.
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Models for the pre-clinical study of ischemic and hemorrhagic stroke
This article presents literature and our own data on animal models of ischemic and hemorrhagic stroke, using in vivo and in vitro methods. Stroke models are reviewed, including focal ischemia, global complete or transient cerebral ischemia, and combined vascular pathologies. The advantages and disadvantages of experimental models and the mechanisms underlying the consequences of ischemic and hemorrhagic brain injury are discussed.
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Models for the pre-clinical study of ischemic and hemorrhagic stroke
This article presents literature and our own data on animal models of ischemic and hemorrhagic stroke, using in vivo and in vitro methods. Stroke models are reviewed, including focal ischemia, global complete or transient cerebral ischemia, and combined vascular pathologies. The advantages and disadvantages of experimental models and the mechanisms underlying the consequences of ischemic and hemorrhagic brain injury are discussed.
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Effect of cyclooxygenase inhibitors, ethylmethylhydroxypyridine succinate and their combinations in a collagen-induced arthritis model in BALB/c mice
Background . Inflammation intensifies lipid peroxidation and damages cell membranes. Therefore, the use of antioxidant and membrane-protective agents in combination with widely prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) can enhance the effect of the therapy. Ethylmethylhydroxypyridine succinate (EMHPS), which has antioxidant and membrane-stabilizing properties, enhances the antiexudative effect of diclofenac sodium and etoricoxib after a single oral administration in rats and mice. Objective . Evaluation of the effect of EMGPS, diclofenac sodium, etoricoxib and combinations of these NSAIDs with EMGPS with a course of oral administration in a collagen-induced arthritis model (CIA) in BALB/c mice. Methods . CIA was modeled by double injection of bovine collagen type II (BC) emulsified with complete Freund's adjuvant into the base of the tail of BALB/c mice, 21 days apart. Arthritis severity, paw edema, hyperalgesia, and motor deficits were recorded. On day 21 after the 2nd BC injection, serum was obtained for evaluation of the concentration of the collagen degradation marker oxyproline and the activity of the antioxidant enzymes catalase and glutathione peroxidase. NSAIDs at a dose of 1 mg/kg, EMHPS at a dose of 25 mg/kg, and combinations of EMHPS with NSAIDs were administered orally daily, starting on day of the 2nd BC injection for 21 days. Results . Mice with CIA developed swelling of the paws, the maximum of an exudative inflammation was observed on days 4–17 after the 2nd injection of BC, then joint deformation was more pronounced, and the concentration of oxyproline in the serum increased. Diclofenac sodium had an antiexudative effect on the 7th day of its administration. Etoricoxib delayed the manifestation of symptoms of arthritis in animals, had an antiexudative effect on the 7th day of its administration, but increased the concentration of oxyproline in serum. EMHPS delayed the manifestation of symptoms of arthritis and reduced the concentration of oxyproline in serum. EMHPS when administered together with diclofenac sodium or etoricoxib had a corrective effect on the severity of symptoms of arthritis and reduced swelling on the 7th day of its administration. EMHPS when administered together with diclofenac sodium or etoricoxib but not NSAIDs and EMHPS per se reduced hyperalgesia on the 7th day of its administration. EMHPS when administered together with diclofenac sodium reduced the level of oxyproline, and when administered with etoricoxib, it prevented the increase in oxyproline level in the serum caused by etoricoxib. Conclusion . The combined use of EMHPS with diclofenac sodium and etoricoxib increases the effect of these NSAIDs in the collagen-induced arthritis model in BALB/c mice.
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Effect of cyclooxygenase inhibitors, ethylmethylhydroxypyridine succinate and their combinations in a collagen-induced arthritis model in BALB/c mice
Background . Inflammation intensifies lipid peroxidation and damages cell membranes. Therefore, the use of antioxidant and membrane-protective agents in combination with widely prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) can enhance the effect of the therapy. Ethylmethylhydroxypyridine succinate (EMHPS), which has antioxidant and membrane-stabilizing properties, enhances the antiexudative effect of diclofenac sodium and etoricoxib after a single oral administration in rats and mice. Objective . Evaluation of the effect of EMGPS, diclofenac sodium, etoricoxib and combinations of these NSAIDs with EMGPS with a course of oral administration in a collagen-induced arthritis model (CIA) in BALB/c mice. Methods . CIA was modeled by double injection of bovine collagen type II (BC) emulsified with complete Freund's adjuvant into the base of the tail of BALB/c mice, 21 days apart. Arthritis severity, paw edema, hyperalgesia, and motor deficits were recorded. On day 21 after the 2nd BC injection, serum was obtained for evaluation of the concentration of the collagen degradation marker oxyproline and the activity of the antioxidant enzymes catalase and glutathione peroxidase. NSAIDs at a dose of 1 mg/kg, EMHPS at a dose of 25 mg/kg, and combinations of EMHPS with NSAIDs were administered orally daily, starting on day of the 2nd BC injection for 21 days. Results . Mice with CIA developed swelling of the paws, the maximum of an exudative inflammation was observed on days 4–17 after the 2nd injection of BC, then joint deformation was more pronounced, and the concentration of oxyproline in the serum increased. Diclofenac sodium had an antiexudative effect on the 7th day of its administration. Etoricoxib delayed the manifestation of symptoms of arthritis in animals, had an antiexudative effect on the 7th day of its administration, but increased the concentration of oxyproline in serum. EMHPS delayed the manifestation of symptoms of arthritis and reduced the concentration of oxyproline in serum. EMHPS when administered together with diclofenac sodium or etoricoxib had a corrective effect on the severity of symptoms of arthritis and reduced swelling on the 7th day of its administration. EMHPS when administered together with diclofenac sodium or etoricoxib but not NSAIDs and EMHPS per se reduced hyperalgesia on the 7th day of its administration. EMHPS when administered together with diclofenac sodium reduced the level of oxyproline, and when administered with etoricoxib, it prevented the increase in oxyproline level in the serum caused by etoricoxib. Conclusion . The combined use of EMHPS with diclofenac sodium and etoricoxib increases the effect of these NSAIDs in the collagen-induced arthritis model in BALB/c mice.
- Open Access
- 2 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 46-58
Ischemic stroke and cardiovascular comorbidity
This review presents data on the prevalence and comorbidities of cardiovascular diseases (CVDs), which are risk factors for the development of acute cerebrovascular accident (ACVA) or myocardial infarction (MI) and the risk of adverse outcomes. CVDs have various markers of cerebral damage, it’s manifested by cognitive decline and down to the development of dementia. The primary pathogenetic mechanism for the development of stroke-associated cardiovascular disease is decreasing cerebral blood flow and microcirculatory network density, i.e. the development of cerebrovascular insufficiency. Most patients with cerebral lesions following stroke have concomitant cardiac pathology, which impacts the post-stroke period and patient survival. In turn, stroke causes cardiac complications and/or the development of newly diagnosed cardiovascular diseases due to impaired autonomic regulation of the cardiovascular system and hemodynamic mechanisms.
- 2 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 46-58
Open AccessIschemic stroke and cardiovascular comorbidity
This review presents data on the prevalence and comorbidities of cardiovascular diseases (CVDs), which are risk factors for the development of acute cerebrovascular accident (ACVA) or myocardial infarction (MI) and the risk of adverse outcomes. CVDs have various markers of cerebral damage, it’s manifested by cognitive decline and down to the development of dementia. The primary pathogenetic mechanism for the development of stroke-associated cardiovascular disease is decreasing cerebral blood flow and microcirculatory network density, i.e. the development of cerebrovascular insufficiency. Most patients with cerebral lesions following stroke have concomitant cardiac pathology, which impacts the post-stroke period and patient survival. In turn, stroke causes cardiac complications and/or the development of newly diagnosed cardiovascular diseases due to impaired autonomic regulation of the cardiovascular system and hemodynamic mechanisms.
- Open Access
- 2 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 86-95
Effect of fabomotizole on behavioral features in Wistar rats with an autism spectrum disorder model induced by prenatal administration of propionic acid during the pubertal period
One of the relevant experimental models of autism spectrum disorder (ASD) is the model induced by the administration of propionic acid (PPA), which replicates key behavioral and neurobiological impairments of the disorder, making it promising for the search of new therapeutic agents. The aim of the study was to investigate the effect of fabomotizole on ASD symptoms induced by prenatal administration of propionic acid in Wistar rats during the pubertal period. The ASD model was induced by administering PPA (500 mg/kg subcutaneously) to female rats on days 12–16 of gestation. The resulting offspring (males) received fabomotizole orally at a dose of 10 mg/kg from postnatal day 6 to day 70. Animal behavior was assessed using tests designed to analyze motor and exploratory activity, anxiety, levels of stereotypy, social behavior, and cognitive functions. In male rats with the ASD model induced by prenatal PPA administration, a decrease in exploratory activity, an increase in anxiety, stereotypical manifestations, aggression, reduced social affinity, and impaired cognitive functions were revealed. Fabomotizole at a dose of 10 mg/kg corrected behavioral impairments in male rats with the ASD model, manifested as increased locomotor and exploratory activity, reduced stereotypy, aggressiveness, and anxiety, and improved social and cognitive functions. The obtained data substantiate the promise of developing fabomotizole as a therapeutic agent for ASD.
- 2 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 86-95
Open AccessEffect of fabomotizole on behavioral features in Wistar rats with an autism spectrum disorder model induced by prenatal administration of propionic acid during the pubertal period
One of the relevant experimental models of autism spectrum disorder (ASD) is the model induced by the administration of propionic acid (PPA), which replicates key behavioral and neurobiological impairments of the disorder, making it promising for the search of new therapeutic agents. The aim of the study was to investigate the effect of fabomotizole on ASD symptoms induced by prenatal administration of propionic acid in Wistar rats during the pubertal period. The ASD model was induced by administering PPA (500 mg/kg subcutaneously) to female rats on days 12–16 of gestation. The resulting offspring (males) received fabomotizole orally at a dose of 10 mg/kg from postnatal day 6 to day 70. Animal behavior was assessed using tests designed to analyze motor and exploratory activity, anxiety, levels of stereotypy, social behavior, and cognitive functions. In male rats with the ASD model induced by prenatal PPA administration, a decrease in exploratory activity, an increase in anxiety, stereotypical manifestations, aggression, reduced social affinity, and impaired cognitive functions were revealed. Fabomotizole at a dose of 10 mg/kg corrected behavioral impairments in male rats with the ASD model, manifested as increased locomotor and exploratory activity, reduced stereotypy, aggressiveness, and anxiety, and improved social and cognitive functions. The obtained data substantiate the promise of developing fabomotizole as a therapeutic agent for ASD.
- Open Access
- 2 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 17-25
Effect of the dipeptide BDNF mimetic (compound GSB-106) on reflex development and monoamine levels in Wistar rats with an experimental autism spectrum disorder
Autism spectrum disorder (ASD) is a neurodevelopmental condition accompanied by alterations in serotonergic, dopaminergic, and noradrenergic systems, as well as delays in early psychomotor and sensorimotor development. One possible approach to correcting these disturbances is the use of BDNF mimetics that regulate synaptic plasticity and neurogenesis. The aim of this study was to investigate the effect of the low-molecular-weight dipeptide BDNF mimetic hexamethylenediamide bis(N-monosuccinyl-L-seryl-L-lysine) (GSB-106) on reflex development and monoamine content in the brain structures of Wistar rats with experimental ASD. The ASD model was induced by administration of sodium valproate (600 mg/kg) on gestation day 12.5. Offspring received GSB-106 orally at a dose of 0.1 mg/kg from postnatal day 7 to 21. The rate of sensorimotor reflex development was evaluated using the “Surface righting” and “Negative geotaxis” tests. Monoamines and their metabolites were quantified by high-performance liquid chromatography with electrochemical detection. GSB-106 improved negative geotaxis performance in both male and female rats with ASD (by 1.8–2.3 times), normalized NA and DOPAC levels in the frontal cortex of females, and reduced DA and 5-HT levels in male brain structures. Thus, GSB-106 exerts a normalizing effect on impaired early behavioral development and monoaminergic systems in rats with an ASD model, suggesting its potential as a promising compound for further investigation.
- 2 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 17-25
Open AccessEffect of the dipeptide BDNF mimetic (compound GSB-106) on reflex development and monoamine levels in Wistar rats with an experimental autism spectrum disorder
Autism spectrum disorder (ASD) is a neurodevelopmental condition accompanied by alterations in serotonergic, dopaminergic, and noradrenergic systems, as well as delays in early psychomotor and sensorimotor development. One possible approach to correcting these disturbances is the use of BDNF mimetics that regulate synaptic plasticity and neurogenesis. The aim of this study was to investigate the effect of the low-molecular-weight dipeptide BDNF mimetic hexamethylenediamide bis(N-monosuccinyl-L-seryl-L-lysine) (GSB-106) on reflex development and monoamine content in the brain structures of Wistar rats with experimental ASD. The ASD model was induced by administration of sodium valproate (600 mg/kg) on gestation day 12.5. Offspring received GSB-106 orally at a dose of 0.1 mg/kg from postnatal day 7 to 21. The rate of sensorimotor reflex development was evaluated using the “Surface righting” and “Negative geotaxis” tests. Monoamines and their metabolites were quantified by high-performance liquid chromatography with electrochemical detection. GSB-106 improved negative geotaxis performance in both male and female rats with ASD (by 1.8–2.3 times), normalized NA and DOPAC levels in the frontal cortex of females, and reduced DA and 5-HT levels in male brain structures. Thus, GSB-106 exerts a normalizing effect on impaired early behavioral development and monoaminergic systems in rats with an ASD model, suggesting its potential as a promising compound for further investigation.
- 1 March 2026
- Published by Allerton Press in Moscow University Biological Sciences Bulletin
- Vol. 81 (1) , 20-25
The Effect of the BDNF Mimetic GSB-106 on Behavior and Inflammation in Wistar Rats with Experimental Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders characterized by deficits in social interaction, stereotypic behavi
- 1 March 2026
- Published by Allerton Press in Moscow University Biological Sciences Bulletin
- Vol. 81 (1) , 20-25
The Effect of the BDNF Mimetic GSB-106 on Behavior and Inflammation in Wistar Rats with Experimental Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders characterized by deficits in social interaction, stereotypic behavi